Penehyclidine hydrochloride attenuates LPS-induced iNOS production by inhibiting p38 MAPK activation in endothelial cells

Mol Biol Rep. 2012 Feb;39(2):1261-5. doi: 10.1007/s11033-011-0857-4. Epub 2011 May 21.

Abstract

The aim of this study was to investigate the inhibitory effect of penehyclidine hydrochloride (PHC) on lipopolysaccharide (LPS)-induced nitric oxide (NO) and inducible nitric oxide synthase (iNOS) production in human endothelial cell. Cultured endothelial cells were pretreated with PHC, followed by LPS treatment. NO activity were determined. iNOS expression and p38 mitogen-activated protein kinase (p38 MAPK) protein expression were measured by Western blot analysis. LPS treatment significantly induced p38 MAPK activation, iNOS expression, and NO production, which could be attenuated by 2 μg/ml PHC pretreatment. Furthermore, our study showed LPS-induced NO production and iNOS expression were suppressed by p38 MAPK inhibitor SB203580 pretreatment. We concluded that PHC attenuates NO production and iNOS expression by suppressing the activation of p38 MAPK pathway, thereby implicating a mechanism by which PHC may exert its protective effects against LPS-induced endothelial cell injury.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Analysis of Variance
  • Blotting, Western
  • Endothelial Cells / metabolism*
  • Enzyme Activation / drug effects*
  • Humans
  • Imidazoles / pharmacology
  • Lipopolysaccharides
  • Nitric Oxide Synthase Type II / metabolism*
  • Pyridines / pharmacology
  • Quinuclidines / metabolism
  • Quinuclidines / pharmacology*
  • p38 Mitogen-Activated Protein Kinases / antagonists & inhibitors*

Substances

  • Imidazoles
  • Lipopolysaccharides
  • Pyridines
  • Quinuclidines
  • penehyclidine
  • NOS2 protein, human
  • Nitric Oxide Synthase Type II
  • p38 Mitogen-Activated Protein Kinases
  • SB 203580